BTG today announces it has acquired Roxwood Medical, an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.
Roxwood’s anchoring catheters (CenterCross, CenterCross Ultra, MultiCross) and microcatheters (MicroCross) offer options for physicians in the crossing of complex lesions and arterial blockages. By incorporating a self-expanding scaffold that stabilises the delivery of a guidewire, Roxwood’s catheters provide positioning accuracy and support to facilitate the crossing of blockages, mitigating guidewire buckling and enabling treatments such as angioplasty, stenting or atherectomy.
“This bolt-on acquisition continues to build BTG’s strength in the interventional vascular space, further expanding our portfolio of differentiated minimally invasive vascular technologies,” said John Sylvester, BTG’s chief commercial officer. “Roxwood’s products complement our existing business and will be offered through our existing Ekos hospital sales force, providing our customers with options to enable treatment of these patients with complex lesions.”
“This is an exciting new chapter for the team at Roxwood and further testament to the utility of the anchoring and microcatheter platforms,” said Mehrdad Farhangnia, Roxwood’s CEO. “With the expanded commercial and clinical reach of BTG, these minimally invasive tools can help far more clinicians successfully treat patients with severe arterial blockages.”
BTG will pay up to US$80 million in cash to acquire Roxwood, comprising US$65 million paid on closing and up to an additional US$15m should certain future commercial milestones be achieved. The transaction is expected to be accretive to adjusted EPS from the second full year of ownership.